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Abstract 
A novel mode to apply photosensitizing drugs specifically to tumor tissue using the 
principles of polyphasic tumor therapies is lined out. Key compounds are tumor specific 
functionalized antibodies with reduced immunogenicity. These bind to drug inclusion 
complexes in a multiplicative manner. Drug inclusion complexes are designed on the basis of 
tethered functionalized ß-cyclodextrin dimers with maximum affinity to porphyrinoid 
photosensitizers forming monomeric chlathrates. To enhance porphyrin-cyclodextrin 
interaction peripheral groups of the porphyrin have to be chemically modified. The 
development of the method is not yet completed. First results are demonstrated. 
Introduction 
In a tumor-bearing organism there are two general routes by which photosensitizers find 
their target tissue: water soluble sensitizers (e.g. the polysulphonated m-tetraphenyl 
porphines or phthalocyanines) enrich in tumor tissue according to pH-equilibria of their 
differently ionized forms (1). Apolar photosensitizers use the lipoprotein pathway to be taken 
up as complexes via the lipoprotein receptors of the tumor cells (2). Both these pathways 
allow for targeting of healthy organs and lead to the wellknown side effects of PDT as well as 
of general chemotherapy. 
To avoid these side effects we started with the simple consideration to construct a 
porphyrinoid -containing inert drug which cannot be taken up by any living cell. Such a drug 
should be functionalized in a manner that it can be bound exclusively to tumor cells. The 
stability of such a drug should be sufficiently high to prevent interaction with the known 
distribution pathways. 
Water soluble complexes: cyclodextrins 
Cyclodextrins are wellknown to form soluble complexes with several water-insoluble drugs 
(3). For example, α-cyclodextrin is admitted as an aid to solubilize prostaglandin Ε 1 for 
injections, γ-cyclodextrin has been used successfully to solubilize tin etio-purpurin for PDT 
purposes (4). In general, aggregates of apolar photosensitizers dissolve in cyclodextrin 
solutions into monomeric host-guest complexes (fig. 1). Highly symmetrical apolar 
phthalocyanins and porphycenes achieve an orientation towards the substructures of the cell 
membrane, and this results in a greatly enhanced uptake velocity by the cell (fig. 2). Despite 
the considerable stability of the 1:1 host-guest complexes (fig. 3) an interaction with the 
lipoprotein pathway is pre-programmed (4). 
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fig. 3 Association equilibria of tetra-t-butyl-phenoxyphthalocyanine and BPEE as revealed by 
TNS-exclusion fluorescence technique. Kp (TTBP) = 14.8 χ 10"6M 
K D(BPEE) = 8.3x10' 6 M 
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Stabilization of the complex: cyclodextrin oligomers 
As a signpost towards stable complexes, BRESLOW and CHUNG (5) investigated the 
complexation of a very simple symmetrical diester, propane diol p-tert.butyl benzoic acid 
diester, with a dimeric "clamshell" ß-cyclodextrin. The stability of the complex exceeded the 
expected value by two orders of magnitude and resulted in a KQ = 10~ 1 0 M comparable with 
the complex stability between antibodies and their antigens. In the mean time several other 
groups constructed cyclodextrin dimers mainly to study and to mimick enzyme-like activities. 
Our first model of a more flexible cyclodextrin dimer to complex porphyrinoid compounds (6) 
has been reconstructed to a box-of-bricks principle (fig. 4): starting from tosylated ß-
cyclodextrin (at positions 2 or 6) we substitute by nucleophilic attack with alkyl diamines of 
short chain length and connect the resulting N-alkyl amines with homobifunctional reagents to 
form ß-cyciodextrin dimers with variable extension including the possibility to introduce 
preformed break-points to finally break the complex at the target site. 
Fx 
fig. 4 Orientation of CD's against guests and bridge forming modalities to achieve optimum 
binding 
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High affinity complexes: anchor structures 
Porphyrins normally contain very short side chains which allow only poor interactions with 
the extended lipophilic cavity of ß-cyclodextrin. More voluminous side chains, like the p-
tert.butyl phenyl group, may allow for much higher stability of the host-guest complex, and by 
the same time may enhance the dipole momentum of the included drug (7). At the moment we 
try to substitute pheophorbide a in C-31 with a p-tert.butyl phenyl ether according to the 
general method given by PANDEY et al (8) in order to better understand anchor functions 
(fig.5). 
fig. 5 Substitution of apolar side chains may enhance complex stability 
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Functionalization of the complex: biotin-avidin complexes 
The biotin-avidin system is wellknown to improve considerably the tumor localization by 
radioscintigraphic methods (9).Thus, biotinylation of the drug-cyclodextrin complexes as well 
as of monoclonal tumor-localizing antibodies is investigated in our group. An anti-CEA 
antibody, B W 431/26, has been biotinylated successfully with up to 7 biotin molecules without 
loosing its affinity to the antigen localized on the surface of LoVo adenocarcinoma cells. 
Biotinylation of ß-cyclodextrins in position 6 over a Cg-spacer was easily achieved using the 
methods yet described. 
Immunological problems: immunogenicity of foreign proteins 
The introduction of foreign proteins, avidin from hen's egg white and mouse monoclonal 
antibodies, into the system raises immunological problems. BOSSLET et al.(10) circumwent the 
problem by constructing an ingenious fusion protein to be applied with the Antibody Directed 
Enzyme Prodrug Therapy (ADEPT) splitting an adriamycin glucuronide at the target site by a 
humanized antibody-ß-glucuronidase complex. This is beyond our today facilities. 
So we study the reduction of immunogenicity by coupling our proteins with unifunctional m-
polyethylene glycols (11) which in a modified form may be used as additional centers to 
accumulate the drug complexes. 
fig. 6 High stability of inclusion complexes prevents sensitizer transport on the lipoprotein 
pathway 
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Outline of the targeting system: polyphasic PDT 
The intended targeting approach is closely related to the ADEPT concept just in phase II-
studies in Great Britain and in Germany. In a first step, biotinylated antibodies with tumor-
localizing properties are injected and then cleared for some days as controlled by 
scintigraphy. In a second step avidin or just avidin-sensitizer chlathrate complexes can be 
injected at very low concentrations due to the high affinity to biotin. We expect concentrations 
as low as 10~1 2M to be able to saturate the antibody-bound biotins excluding any toxicity of 
ß-cyclodextrin. The multiplicative effect due to multiple binding sites of avidin and the 
polyvalency of the drug complexes should allow for an accumulation of 10 6 to 10 s molecules 
of sensitizer per tumor cell assuming 5 χ 10 4 antigenic binding sites. This is fairly in the range 
of phototoxic concentrations and should allow for irreversible damage by laser irradiation (fig. 
6). 
fig. 7 Sequential administration of antibodies and drug complexes leads to accumulation of 
sensitizer due to polyvalency of the single compounds 
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A glance over the plate's border: tumor chemotherapy 
We should take in mind that complexation of drugs by cyclodextrins is originally invented to 
solubilize water-insoluble drugs in general. Porphyrinoid binding is only one of the possible 
applications. Looking over the manifold of today anti-cancer agents there are several potent 
but harmful drugs which could be detoxified by inclusion into cyclodextrin oligomers and, by 
chance, transferred to its target without considerable side effects. Moreover, there are several 
potent anti-cancer drugs which cannot be given to a patient because of their high general 
toxicity. Some of them are porphyrin derivatives. So, in future such a system may be helpful to 
revive and to modify general chemotherapy to a curative modality without its inherent side 
effects. 
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